Read important information about Valley's continued commitment to serving our patients and respecting their privacy, regardless of immigration status.
Read More
Clinical Trials
To view the clinical trials Valley currently has available, please use the search field or select a clinical specialty from the drop-down list below. Be sure to check back frequently, as we are always adding new studies.
For more information about any of our clinical trials, please email [email protected] or call 201-447-8453. (For cancer clinical trials, please call 201-634-5792.)
A081801 Alchemist
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Principal Investigator(s): Jason W. Suh, MD
Status: Open and enrolling
ACCLAIM 1
A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer
Principal Investigator(s): Eli Kirshner, MD
Status: Open and enrolling
EA5182
Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator(s): Eli Kirshner, MD
Status: Open and enrolling
PACIFIC-9
A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy
Principal Investigator(s): Eli Kirshner, MD
Status: Open and enrolling
TROPION LUNG08
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)
Principal Investigator(s): Eli Kirshner, MD
Status: Open and enrolling